Targeting Glycosylation Aberrations to Improve the Efficiency of Cancer Phototherapy - CNRS - Centre national de la recherche scientifique Accéder directement au contenu
Article Dans Une Revue Current Cancer Drug Targets Année : 2019

Targeting Glycosylation Aberrations to Improve the Efficiency of Cancer Phototherapy

Résumé

The use of photodynamic therapy in cancer still remains limited, partly because of the lack of photosensitizer (PS) specificity for the cancerous tissues. Various molecular tools are available to increase PS efficiency by targeting the cancer cell molecular alterations. Most strategies use the protein-protein interactions, e.g. monoclonal antibodies directed toward tumor antigens, such as HER2 or EGFR. An alternative could be the targeting of the tumor glycosylation aberrations, e.g. T/Tn antigens that are truncated O-glycans over-expressed in numerous tumors. Thus, to achieve an effective targeting, PS can be conjugated to molecules that specifically recognize the Oglycosylation aberrations at the cancer cell surface.
Fichier non déposé

Dates et versions

hal-03136056 , version 1 (09-02-2021)

Identifiants

Citer

Guillaume Poiroux, Annick Barre, Pierre Rougé, Hervé Benoist. Targeting Glycosylation Aberrations to Improve the Efficiency of Cancer Phototherapy. Current Cancer Drug Targets, 2019, 19 (5), pp.349-359. ⟨10.2174/1568009618666180628101059⟩. ⟨hal-03136056⟩
15 Consultations
0 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More